Houston, TX
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Clayton Foundation For Research, founded in 1965, is a mid-sized nonprofit in the Medical Research sector that reported $11.0M in total revenue in fiscal year 2023. Revenue surged 67% from the prior year, signaling strong growth momentum. Net assets of $123.5M represent 134 months of operating reserves.
The primary mission is to conduct medical research in conjunction with hospitals for the purpose of discovering the cause, prevention and cure of diseases for the benefit of mankind. The secondary mission is to transfer the resulting medical research discoveries from the laboratory to the use of the general public by patenting and licensing such technology for development into drugs or other products for the use and benefit of mankind through the Foundation's supporting entities.
A research project at Baylor College of Medicine in gene and protein therapy focuses on inappropriate cell division and cell death within the human body. Much of the work is devoted to intraocular...
A research project at Baylor College of Medicine in gene and protein therapy focuses on inappropriate cell division and cell death within the human body. Much of the work is devoted to intraocular angiogenesis, with particular attention to: 1) the signals that control this process, 2) the development of animal models of human ocular disease, and 3) development of potential therapies. New targets have been identified and potential therapeutic agents are being developed and tested for the treatment of wet AMD, Diabetic Retinopathy, and Retinopathy of Prematurity. Patent applications have been filed by RDF, one of the Foundation's supporting entities, on several discoveries arising out of this research. Licensing efforts by RDF resulted in a license to a commercial company that, using project technology, completed a Phase I human clinical trial with gene therapy to treat wet age-related macular degeneration.
The conduct of a longstanding research program at the University of Texas M. D. Anderson Cancer Center, the purpose of which is to design and develop novel targeted therapeutic agents that target a...
The conduct of a longstanding research program at the University of Texas M. D. Anderson Cancer Center, the purpose of which is to design and develop novel targeted therapeutic agents that target a powerful human toxin to specifically destroy cancer cells for the treatment of numerous cancer targets and other disease indications. A number of collaborations have been undertaken with researchers at various institutions (e.g., University of California San Diego). Patent applications have been filed by Research Development Foundation (RDF), a tax exempt supporting organization of the Foundation (see schedule R, Part III), on more than twenty discoveries, and a number of patents have been issued. Licensing efforts have been ongoing and have resulted in several licenses.
A research program at Baylor College of Medicine in Houston is directed toward glaucoma, the second leading cause of permanent blindness in the world. More than 3 million Americans live with...
A research program at Baylor College of Medicine in Houston is directed toward glaucoma, the second leading cause of permanent blindness in the world. More than 3 million Americans live with glaucoma, and it is estimated that perhaps millions more remain undiagnosed. The research includes opportunities to treat intraocular pressure (IOP) in a more targeted way that is independent of current medical therapies. State of the art technologies have been developed and are being used to analyze and characterize the molecular changes associated with the early stages of the diseases. The researchers objective is the identification of new potential therapies for glaucoma.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $11,043,790 | $6,604,622 | +0.7% |
| Expenses | $10,750,530 | $10,006,620 | +0.1% |
| Net Income | $293,260 | $-3,401,998 | -1.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Jarred W Sloan | Trustee, President, Treasurer | 20.00 |
Officer
Director
|
$274,083 | $97,800 | $761,256 |
| Robert M Wallace | Trustee, Vice President | 20.00 |
Officer
Director
|
$203,370 | $97,800 | $761,256 |
| Lynn P Carter | Trustee | 8.00 |
Director
|
$97,315 | $97,800 | $761,256 |
| Joan S Dunlap | Trustee, VP, Secretary | 4.00 |
Officer
Director
|
$126,473 | $88,019 | $588,105 |
| Brian W Crozier | Trustee, Chairman | 5.00 |
Officer
Director
|
$97,315 | $50,086 | $395,392 |
| Thomas J Brorby | Trustee, Deceased | 5.00 |
Officer
Director
|
$80,872 | $16,600 | $303,562 |
| Robert L Evans | VP, Assistant Treasurer | 40.00 |
Officer
|
$210,000 | $81,846 | $291,846 |
| Kimberly A Shipley | Assistant Secretary | 40.00 |
Officer
|
$173,267 | $76,336 | $249,603 |
| Lawrence H Cheung | Project Researcher | 40.00 |
|
$114,406 | $40,035 | $154,441 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $11,043,790 | $10,750,530 | $130,572,468 | $293,260 |
| 2022 | $6,604,622 | $10,006,620 | $112,685,763 | $-3,401,998 |
| 2021 | $10,982,705 | $10,317,749 | $144,911,994 | $664,956 |
| 2020 | $10,487,160 | $9,206,656 | $120,838,913 | $1,280,504 |
Compare Clayton Foundation For Research with other nonprofits in Texas and across the country.